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Peer review under rwww.sciencedirect.comEDITORIALAdvanced knowledge in drug metabolism and
pharmacokineticsDrug metabolism and transport in human organs, such as in the
liver, intestine, and kidney, control the concentrations of a drug
and its metabolites in the circulating system and target organs in a
certain period of time following drug administration. The pharma-
cokinetic properties will consequently determine therapeutic efﬁ-
cacy and inﬂuence toxicological effects. Changes of drug
metabolism and pharmacokinetics may result in signiﬁcant inter-
individual variations in therapeutic efﬁcacy and adverse drug
reactions. Therefore, understanding drug metabolism and pharma-
cokinetic properties is essential for drug development and clinical
therapy. Growing researches in these areas also promote the
development of novel approaches to implementation of persona-
lized medicine or precision medicine. This special issue consists of
a set of original research and review articles providing recently-
gained information in these areas. As the guest Editors, we would
like to appreciate the journal for providing us the opportunity to
share the information and thank all authors for their contributions.
Cytochrome P450 (CYP or P450) enzymes are the major super-
family of phase I drug-metabolizing enzymes. Extensive studies have
demonstrated the impact of hepatic P450 functions and regulation on
drug metabolism and responses. However, intestinal P450-mediated
drug metabolism is an important factor dictating ﬁrst-pass metabolism
and oral bioavailability. Fang Xie and colleagues provide an updated
review on the role of intestinal P450 enzymes in drug disposition (see
a story for the front cover)1. The utility of genetically engineered
mouse models, which target the P450-reductase (CPR) on speciﬁc
tissues, in deﬁning the contribution of intestinal and hepatic P450s to
drug metabolism and pharmacokinetics is also discussed. CYP2B6 is
one isoform among P450 superfamily and it metabolizes 2%–10% of
clinically-used drugs. William Hedrich and colleagues present an
overview on key players in the regulation of CYP2B6 expression and
functions and highlight recent advanced knowledge in CYP2B6-
mediated drug–drug interactions2. Transporters are another super-
family of proteins involved in drug absorption, distribution, and
elimination. In particular, renal drug transporters play an important
role in secretion and reabsorption of drugs in the kidney. Jia Yin and
Joanne Wang give a comprehensive review on the functional16/j.apsb.2016.08.003
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esponsibility of Institute of Materia Medica, Chinese Accharacteristics of major human renal drug transporters and their
involvement in clinically signiﬁcant pharmacokinetic drug–drug
interactions (see a story for the back cover)3.
Several key transcription factors, including pregnane X receptor
(PXR), constitutive androstane receptor (CAR), farnesoid X receptor
(FXR), hepatocyte nuclear factor 4 alpha (HNF4α), and estrogen
receptor (ER), have been demonstrated to play important roles in the
regulation of gene expression of drug-metabolizing enzymes and
transporters. Several research and review articles have focused on
novel aspects of these transcription factors in the regulation of drug
metabolism and transport gene expression. Jiong Yan and Wen Xie
describe a historical overview on the discovery of PXR and CAR as
xenobiotic receptors4. Trent Brewer and Taosheng Chen discuss
several PXR protein variants and their impact on drug metabolism
and therapeutic responses5. Shinhee Park and colleagues characterize
gene expression of CAR-targeted drug-metabolizing enzymes and
transporters in mouse intestine6. Hong Lu gives a comprehensive
review on HNF4α-controlled gene expression and crosstalks of
HNF4α with diverse extracellular and intracellular signaling path-
ways in the modulation of hepatic drug metabolism and lipid
homeostasis7. Yan Zhu and colleagues provide a review on the
critical roles of FXR in the control of bile acid homeostasis and
illustrate the molecular mechanisms behind dysregulation of bile
acids in promoting liver injury and nonalcoholic fatty liver disease8.
Lai Peng and colleagues determine the role of FXR in establishment
of ontogeny of phase I drug-metabolizing enzyme gene expression in
mouse liver9. Sung-joon Cho and colleagues demonstrate that
upregulation of UGT1A9 gene expression by estradiol is a transcrip-
tional response to the activation of ERα receptor10.
Pharmacokinetics/pharmacodynamics (PK/PD) modeling and
simulation offer quantitative understanding of drug exposure and
response, guide the selection of dose and dose regimen, and
predict interindividual variability towards precision medicine.
Xiaomei Zhuang and Chuang Lu provide an overview on the
concept and methodology of physiologically based pharmacoki-
netic (PBPK) modeling11. Case studies are presented to illustrate
how PBPK modeling and simulation may beneﬁt drug discoveryMedica, Chinese Academy of Medical Sciences. Production and hosting by
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nimodipine as a model drug to demonstrate the potential effects of
age and polymorphic form on pharmacokinetics in rats12. Xi-ling
Jiang and colleagues describe the development of a new mechan-
ism-based PK/PD model to characterize the thermoregulatory
effects of serotonergic drugs in mouse models, which may serve
as a new framework for the investigation of thermoregulatory or
other neuropharmacological effects of serotonergic agents13.
Distribution of a drug to target tissues is essential to achieve
therapeutic effects, while production of reactive metabolites may
provoke xenobiotics-induced tissue and organ damage. Hong Shen
and colleagues demonstrate tissue distribution and tumor uptake of
a folate receptor-targeted, anticancer agent epothilone folate
conjugate in xenograft tumor mouse models following systemic
administration14. Pengcheng Wang and colleagues provide an
overview on the metabolic pathways of isoniazid and their
possible associations with isoniazid-induced liver injury15. In
addition, Jonathan Choiniere and Li Wang provide a mini-review
on the impact of environmental arsenic on gut microbe and
possible link to arsenic-induced carcinogenesis16.
We hope this special issue would serve as a valuable informa-
tion resource for our readers to gain more knowledge in the ﬁelds
of drug metabolism and pharmacokinetics.References
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